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Objective: Adrenal failure is common in critically ill patients, 
particularly those with sepsis. As liver failure and sepsis are both 
associated with increased circulating levels of endotoxin and 
proinflammatory mediators and reduced levels of apoprotein-ll 
high-density lipoprotein, we postulated that adrenal failure may 
be common in patients with liver disease. 
Design: Clinical study. 
Setting: Liver transplant intensive care unit. 
Patients: The study cohort included 340 patients with liver 
disease. 
Interventions: Based on preliminary observational data, all 
patients admitted to our 28-bed liver transplant intensive care 
unit (LTICU) undergo adrenal function testing. An honest broker 
system was used to extract clinical, hemodynamic, medication, 
and laboratory data on patients admitted to the LTiCU from March 
- 2002 to March 2004. A random (stress) cortisol level <20 1L9/dL 
in a highly stressed patient (respiratory failure, hypotension) was 
used to diagnose adrenal insufficiency. In all other patients, a 
random cortisol level <15 1L9/dL or a 30-min level <20 1L9/dL 
post-low-dose (1 ILg) cosyntropin was considered diagnostic of 
adrenal insufficiency. Patients were grouped as follows: a) 
chronic liver failure; b) fulminant hepatic failure; c) patients 
immediately status post-orthotopic liver transplantation receiving 
a steroid-free protocol of immunosuppression; and d) patients 
status post-remote liver transplant E~S months). The decision to 
treat patients with stress doses of hydrocortisone was at the 
discretion of the treating intensivist and transplant surgeon .. 
Measurements and Main Results: Two-hundred and forty-five 
(72%) patients met our criteria for adrenal insufficiency (the 
hepatoadrenal syndrome). Eight (33%) patients with fulminant 
hepatic failure, 97 (66%) patients with chronic liver disease, 
31 (61 %) patients with a remote history of liver transplantation, 
and 109 (92%) patients who had undergone liver transplantation 
under steroid-free immunosuppression were diagnosed with ad-
renal insufficiency. The high-density lipoprotein level at the time 
of adrenal testing was the only variable predictive of adrenal 
insufficiency (p < .0001). In vasopressor-dependent patients with 
adrenal insufficiency, treatment with hydrocortisone was associ-
ated with a significant reduction (p = .02) in the dose of norepi-
nephrine at 24 hrs, whereas the dose of norepinephrine was 
significantly higher (p = .04) in those patients with adrenal failure 
not treated with hydrocortisone. In vasopressor-dependent pa-
tients without adrenal insufficiency, treatment with hydrocorti-
sone did not affect vasopressor dose at 24 Ius. One hundred and 
forty-one patients (26.4%) died during their hospitalization. The 
baseline serum cortisol was 18.8 ± 16.2 1L9/dL in the nonsurvi-
vors compared with 13.0 ± 11.8 1L9/dL in the survivors (p < 
.001). Of those patients with adrenal failure who were treated with 
glucocorticoids, the mortality rate was 26% compared with 46% 
(p = .002) in those who were not treated. In those patients 
receiving vasopressor agents at the time of adrenal testing, the 
baseline cortisol was 10.0 ± 4.8 1L9/dL in those with adrenal 
insufficiency compared with 35.6 ± 21.2 1L9/dL in those with 
normal adrenal function. Vasopressor-dependent patients who 
did not have adrenal failure had a mortality rate of 75%. 
Conclusions: Patients with liver failure and patients post-liver 
transplantation have an exceedingly high incidence of adrenal 
failure, which may be pathophysiologically related to low levels of 
high-density lipoprotein. Treatment of patients with adrenal fail-
ure may improve outcome. High baseline serum cortisol levels 
may be a maker of disease severity and portend a poor prognosis. 
(Crit Care Med 2005; 33:1254-1259) 
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Once considered a rare diagno-sis in the intensive care unit (leU). adrenal failure is be-
ing reported with increased 
frequency in critically ill patients with 
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sepsis, HIV infection, and head injury and 
following cardiac surgery (1-4). Adrenal 
failure may be associated with structural 
damage to the adrenal gland, pituitary 
gland. or hypothalamus; however, many 
critically ill patients develop reversible 
failure of the hypothalamic-pituitary-
adrenal axis (5). Activation of the hypo-
thalamic-pituitary-adrenal axis with the 
release of cortisol is an essential compo-
nent of the general adaptation to illness 
and stress and contributes to the mainte-
nance of cellular and organ homeostasis. 
This is clearly demonstrated in adrenalec-
tomized animals, who succumb rapidly to 
hemorrhagic and septic shock. with ste-
roid replacement being protective against 
these challenges (6, 7). Furthermore. An-
nane and colleagues (8) demonstrated 
that treatment with stress doses of hydro-
cortisone (and supplemental mineralo-
corticoid) improved survival in a sub-
group of septic shock patients with 
adrenal failure. 
The fact that adrenal failure is com-
mon in critically ill patients and that 
treatment with stress doses of glucocor-
ticoids may be beneficial is difficult to 
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dispute. What remains controversial at 
this time is the diagnosis of this disorder 
(9). Circulating cortisol is bound to cor-
ticosteroid-binding globulin with < 10% 
in the free bioavailable form. During 
acute illness, there is an acute decline in 
the concentration of corticosteroid-
binding globulin as well as decreased 
binding affinity for cortisol, resulting in 
an increase in the free biologically active 
fraction of the hormone (10, 11). Corti-
costeroid-binding globulin is also re-
duced in liver disease (12). In addition, 
both the number and affinity of the in-
tracellular glucocorticoid receptor may 
be down-regulated (tissue resistance) 
during acute illness (13-16). These data 
suggest that a serum cortisol (total) level 
may not be an accurate reflection of glu-
cocorticoid activity af the cellular level. 
Not withstanding these limitations, and 
in the absence of a readily available diag-
nostic test with greater specificity, we 
and others have demonstrated that the 
baseline serum cortisol level may be use-
ful for diagnosing adrenal failure in the 
critically ill as well as being a prognostic 
marker (1, 17, 18). There appears to be 
general consensus that a random cortisol 
level (total) <15 f.Lg/dL in an leU patient 
is diagnostic of adrenal insufficiency (19). 
In addition. we contend that a level <20 
f.Lg/dL in a highly stressed patient (hypo-
tensive, hypoxic) is abnormal (1, 5, 9). 
The incidence of adrenal failure in 
septic shock has been reported to be as 
high as 61 % (1). As sepsis and end-stage 
liver disease have a number of pathophys-
iologic mechanisms in common (endo-
toxemia, increased levels of proinflamma-
tory mediators, decreased levels of 
apoprotein -Alhigh -density lipoprotein), 
we speculated that adrenal failure may be 
common in patients with end-stage liver 
disease (20-22). Indeed, in preliminary 
data we have observed a high incidence of 
adrenal failure in patients with end-stage 
liver disease and patients post-liver trans-
plantation (23). Furthermore. we and 
others have noted an association between 
low levels of high-density lipoprotein 
(HDL) and adrenal failure (23, 24). Based 
on these observations, we currently rou-
tinely assess adrenal function in patients 
in our liver transplant leu (LTICU). 
MATERIALS AND METHODS 
This study was conducted in the 28-bed 
L TICU in ,vlontefiore Hospital, University of 
Pittsburgh, Pittsburgh, PA. Patients who have 
undergone liver transplantation as well as pa-
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tients with acute and chronic liver failure and 
patients with gastrointestinal bleeding are ad-
mitted to the LTICU. Based on preliminary 
data, all patients (except those concurrently 
receiving glucocorticoids) admitted to the 
L TICU from March 2002 underwent adrenal 
function testing (as outlined subsequently) 
(23). The University of Pittsburgh Medical 
Center has a comprehensive electronic medi-
cal record system that archives patient clinical 
and laboratory data in a number of separate 
database systems" An honest broker system 
was used to retrospectively extract clinical and 
laboratory data on patients who underwent 
adrenal function testing from March 2002 to 
March 2004. An honest broker system uses a 
third party not involved in the study to extract, 
collate, and de-identify data files. De-identified 
data files that included diagnoses, transplant 
status, medication, physiologic, and hemody-
namic data from the ICU information system 
as well as laboratory data were linked to form 
a relational database. The laboratory data in-
cluded cortisol levels, liver function tests, co-
agulation profile, serum electrolytes, and lipid 
profile. The data extracted from the ICU infor-
mation system included the hourly hemody-
namic profile, use and dosages of vasopressor 
agents (norepinephrine), and medications. 
The honest broker validated the extracted data 
on all patients included in the study from a 
review of the primary source (i.e .. the patients' 
electronic medical records). Permission to 
perform this study was obtained from the Uni-
versity of Pittsburgh Institutional Review 
Board, During the study period, patients un-
dergoing liver transplantation (cadaveric, liv-
ing related, and non-heart-beating donors) 
were treated with a steroid-sparing regimen of 
immunosuppression. Patients received Cam-
path (Alemtuzumab/anti-CD 52 monoclonal 
antibody, Berlix Laboratories, Richmond CAl 
or thymoglobulin. Patients included in this 
protocol received 1 g of methylprednisolone to 
limit/prevent the cytokine reactions following 
the infusion of the lymphoid-depleting agents. 
Postoperative immunosuppression included 
oral FK 506 (tacrolimus) started on postoper-
ative day 1. with the dose adjusted to obtain a 
whole blood trough level between 6 and 12 
fLg/mL as clinical circumstances dictated. 
Glucocorticoids were not used in the postop-
erative immunosuppressive regimen unless 
biopsy-proven rejection was demonstrated. 
As part of the routine diagnostic workup of 
patients admitted to the LTICU, adrenal func-
tion testing was performed as follows: a) In 
patients requiring vasopressor agents, hypo-
tensive patients undergoing volume resuscita-
tion, and patients with hypoxic respiratory 
failure, a random ("stress") cortisol level (total 
serum cortisol) was obtained on admission to 
the LTICU: b) patients with liver disease who 
did not meet these criteria (as listed previ-
ously) underwent a low-dose (1 fLg) cosyn-
tropin stimulation test within 24 hI'S of admis-
sion to the L TICU (1); and c) in patients post-
liver transplantation, serum "cortisol" levels 
were measured daily from the second postop-
erative day and a low-dose cosyntropin stim-
ulation test was performed when the serum 
cortisol level was <15 fLg/dL. Patients who did 
not meet our criteria for adrenal insufficiency 
(discussed subsequently) and who either had a 
low level of high-density lipoprotein (HDL) 
«20 mg/dL) or had a progressive deteriora-
tion in liver function underwent repeat adre-
nal function testing. 
The serum cortisol results were available 
within 24 hI'S of testing (usual delay of approx-
imately 6 hI'S except on weekends)' The deci-
sion to treat patients with stress doses of hy-
drocortisone was at the discretion of the 
treating intensivist and/or transplant surgeon. 
When treatment was initiated, a standard dose 
of 100 mg of hydrocortisone intravenously ev-
ery 8 hrs was used; this was then weaned as 
clinically indicated. 
The cortisol was measured by a competi-
tive immunoassay using direct chemilumines-
cent technology (Centaur Analyzer, Bayer), 
Total cholesterol and triglyceride were mea-
sured by a colorimetric assay "(cholesterol ox-
idase and lipase-glycerol-kinase. respectively), 
whereas the HDL was measured by dextran 
sulfate extraction followed by the cholesterol 
oxidase reaction (Vitros Analyzer, Ortho Clin-
ical Diagnostics). Low-density lipoprotein was 
calculated from the total cholesterol, HDL, 
and triglyceride concentration, 
Data Analysis. Patients who had received 
systemic glucocorticoids for >30 days during 
the previous year were excluded from this 
study. Similarly, patients who had received 
systemic glucocorticoids for between 10 and 
30 days in the previous 6 months, as well as 
patients concurrently receiving glucocorti-
coids or who were treated with glucocorticoids 
during their hospital stay, were excluded from 
the study (5). For the purposes of this study, 
we used the following conservative criteria for 
the diagnosis of adrenal failure: a) a random 
(stress) cortisol level of <20 fLg/dL in patients 
with hypoxemic respiratory failure, with hypo-
tension (systolic blood pressure <90 mm Hg), 
or requiring vasopressor agents for blood pres-
sure support (5, 9); and b) a random level of 
<15 fLg/dL or a 30-min post-low-dose cosyn-
tropin stimulation test level of <20 fLg/dL in 
non-highly stressed patients (5. 9. 19). Pa-
tients were grouped as follows: a) chronic liver 
failure; b) fulminant hepatic failure; c) patient 
status post-orthotopic transplant receiving 
steroid-free immunosuppression; and d) pa-
tient status post-remote liver transplant (;;::6 
months). 
Statistical Analysis. Summary statistics 
were compiled to allow a description of the 
patient population and the predefined sub-
groups. Statistical analysis was done using 
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Ness 2004 (Kaysville, Ur). Chi-square analy-
sis was used to compare categorical data. Con-
tinuous data were compared using Student's 
I-test. The Mann-Whitney U test was used for 
data that failed tests of normality. Pearson's 
correlation coefficient was used to determine 
the association between the stress cortisol 
level and serum albumin. Unless otherwise 
stated, all data are expressed as mean ::'::5D, 
with statistical significance declared ior prob-
ability values :':::.05. 
RESULTS 
During the period under study, 452 
patients underwent adrenal function test-
ing, Sixty-two patients had undergone 
small bowel, multivisceral, pancreas, or 
kidney transplant and were excluded. A 
further 50 patients had received systemic 
corticosteroids in the 12 months preced-
ing admission to the LTICU or during 
their current admission and were ex-
cluded. The study cohort comprised 340 
patients with a history of liver disease. 
Twenty-four (7%) patients had fulminant 
hepatic failure, 146 (43%) had chronic 
liver disease, 51 (15%) had undergone 
remote liver transplantation, and 119 
(35 1}6) had recently undergone liver 
transplantation under steroid-free immu-
nosuppression. Of the patients with 
chronic liver disease, 76 (52%) had eth-
anolic liver disease, 23 (16%) had hepati-
tis C, and 14 (10%) had nonalcoholic 
steatohepatitis. The mean age of the co-
hort was 53 ± 11 yrs (fulminant liver 
failure 39 ± 16 yrs; all other 54 ± 10 yrs). 
There were 175 (58%) male patients. 
Two-hundred and forty-five (72%) pa-
tients met our criteria for adrenal insuf-
ficiency. Eight (33%) patients with fulmi-
nant hepatic failure, 97 (66%) patients 
with chronic liver disease, 31 (61%) pa-
tients with a remote history of liver trans-
plantation, and 109 (92%) patients who 
had undergone recent liver transplanta-
tion (with a steroid-sparing immunosup-
pressive regimen) were diagnosed with 
adrenal insufficiency. The random serum 
cortisol levels as well as the liver function 
tests, serum creatinine concentration. 
and cholesterol levels in the patient sub-
groups stratified by adrenal function are 
listed in Table 1. The HDL level at the 
time of adrenal testing was the only vari-
able predictive of adrenal insufficiency (p 
< .0001), The correlation coefficient be-
tween the random serum cortisol level 
and the serum albumin concentration 
was .02 (r2 = .0004, p = .83). 
One hundred and sixty-six patients 
were being treated with pressor agents at 
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the time of adrenal testing. Seventy-five 
percent of the pressor-dependent patients 
had adrenal insufficiency. The baseline 
serum cortisol was 16.8 ± 12.6 f,Lg/dL in 
the pressor-dependent patients compared 
with 13.1 ::':: 1l.4 f,Lg/dL (nonsignificant) 
in those patients not receiving pressor 
agents. In those patients receiving vaso-
pressor agents at the time of adrenal test-
ing, the baseline cortisol was 10.0 ± 4.8 
f,Lg/dL in those with adrenal insufficiency 
compared with 35.6 ::':: 21.2 f,Lg/dL in 
those with normal adrenal function. The 
pressor requirements in the vasopressor-
dependent patients at baseline and after 
24 hrs of hydrocortisone treatment, and 
the comparable pressor requirements of 
those patients who did not receive hydro-
cortisone, stratified by adrenal function 
are listed in Table 2. 
Of the 119 patients undergoing trans-
plantation with steroid-free immunosup-
pression, 109 (92%) were diagnosed with 
adrenal insufficiency. Following the large 
intraoperative dose of methylpred-
nisolone, the serum "cortisol" level fell to 
a nadir of 9.2::':: 5.2 f,Lg/dL. Fifty-one pa-
tients demonstrated a rapid postoperative 
recovery of hepatic function along with 
an increase in HDL and cortisol levels, 
and the remaining 68 (57%) were treated 
with hydrocortisone. Eleven of these pa-
tients had depressed left ventricular func-
tion (low cardiac index, high systemic 
vascular resistance) as determined by in-
vasive hemodynamic monitoring. 
One hundred and forty-one patients 
(26.4%) died during their hospitalization, 
and the mortality rate for each subgroup 
was as follows: fulminant hepatic failure 
30%, chronic liver disease 56%, remote 
liver transplantation 62%, and recent 
liver transplantation 18%. The mortality 
rate was 59% in the patients receiving 
vasopressor agents at the time of adrenal 
testing compared with 28% in the vaso-
pressor independent patients (p < .001). 
The baseline serum cortisol was 18.8 ::':: 
16.2 f,Lg/dL in the nonsurvivors compared 
with 13.0 ± 11.8 f,Lg/dL in the survivors 
(p < .001). The mortality rate was 38.8% 
for patients diagnosed with adrenal fail-
ure compared with 55.9% (p = .005) with 
normal adrenal function. Of those pa-
tients with adrenal failure who were 
treated with glucocorticoids, the mortal-
ity rate was 26% compared with 46% (p 
= .002) in those who were not treated 
with glucocorticoids. The mortality rate 
was 75% in those vasopressor-dependent 
patients who did not have adrenal failure. 
DISCUSSION 
The main finding of our study was the 
surprisingly high incidence of adrenal 
failure in critically ill patients with liver 
disease, an entity for which we have 
coined the term "hepatoadrenal syn-
drome." Liver failure is well recognized 
to cause renal (hepatorenal syndrome) 
and pulmonary (hepatopulmonary syn-
Table 1. Clinical data and laboratory data grouped according to adrenal function 
Normal Adrenal 
Adrenal Failure Function 
(n = 245) (n = 95) p Value 
Age, yrs 54 ± 11 52::':: 12 .32 
MAP, mm Hg 76::':: 17 82 ± 17 .14 
Mechanical ventilation, n (%) 179 (73) 73 (77) ,58 
Vasopressor agent, n ('Yo) 124 (51) 42 (44) .54 
Random cortisol, ILgidL 
All patients 9.3 ± 4.1 30.4 ::':: 19.5 <.001 
Fulminant 11.6::':: 2.7 29.6::':: 9.6 <.001 
Chronic LD 10.8 ± 4.1 32.6 ± 22.8 <.001 
Transplant 8.0 ± 3.8 29.3::':: 20.0 <.001 
SP. Transplant 8.3 ± 3,7 21.2 ± 8.1 <.001 
Total bilirubin, ILmoi/L 9.5 ± 9.6 8.2::':: 9.4 .31 
lNR 1.7 ± 0.9 1.8 ± 0.8 .20 
Serum albumin. giL 2.3 ± 0.7 2.5 ::':: 0.6 .37 
Serum creatinine, ILmollL 1.8::':: 3.7 2.0::':: 2.9 .56 
LDL cholesterol. mg/dL 55.8 ::':: 32.5 65.8 ± 54.3 .38 
HDL cholesterol, mgJdL 8.2 ± 7.6 28.4 ± 14.4 <.0001 
Mortality, n (1M,) 95 (39) 53 (56) .005 
Treated with steroids 41/156 (26) 
Not treated with steroids 41/89 (46)G 
MAP. mean arterial pressure: LD, liver disease; SP, steroid-sparing immunosuppression: INR. 
international normalized ratio; LDL, low-density lipoprotein; HDL, high·density lipoprotein. 
"p = .002 for treatment with steroids compared with no steroids. 
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Table 2. Baseline and 24-hr norepinephrine dose stratified by adrenal function and treatment with 






fl.g/kg/min p Value 
Normal adrenal function 
All In = 42) 
Treateu with steroids (n = ll) 
No steroius In = 31) 
0.17 :+: 1J.l6 
0.24 :+: 0.15 
0.15 :+: 0.19 
0.18 :+: 0.15 
0.28::': 0.22 





TreateJ with steroids (n = 98) 
No steroiJs (n = 26) 
0.17 ::': 0.19 
0.07 :+: 0.06 




drome) disease; however, the association 
between liver failure and adrenal insuffi-
ciency has not been well studied. Singh 
and colleagues (25) reported a single case 
of adrenal insufficiency following liver 
transplantation. Harry and coworkers 
(26) demonstrated an abnormal high-
dose cosyntropin stimulation test in 28 of 
45 (62%) patients with acute liver failure. 
In a cohort of 38 "nonstressed" patients 
with end-stage liver disease, McDonald et 
al. (12) reported a 64% reduction in peak 
plasma cortisol following insulin-induced 
hypoglycemia and a 39% reduction fol-
lowing a high-dose cosyntropin test when 
compared with healthy controls. 
In patients with adrenal insufficiency, 
the mortality rate was lower in those pa-
tients treated with glucocorticoids. Al-
though this was a nonrandomized study, 
these data support the contention that 
treatment of critically ill patients with 
adrenal insufficiency (low baseline corti-
sol level) may improve outcome (5, 19). 
Furthermore, as noted previously by An-
nane and colleagues (18), a very high 
serum cortisol was associated with a high 
mortality rate. Hence. untreated patients 
with adrenal insufficiency (low cortisol 
levels) and patients with a very high cor-
tisollevel may have a high mortality rate. 
In our study, we used a stress (ran-
dom) cortisol level to diagnose adrenal 
insufficiency in highly stressed critically 
ill patients and performed a low-dose (1-
f,Lg) cosyntropin test in less severely 
stressed ICU patients (5. 9). We believe 
this to be the most practical approach to 
the diagnosis of adrenal insufficiency in 
critically ill patients at this time. Using 
this diagnostic approach. 72% of the pa-
tients studied had adrenal insufficiency. 
Some would argue that the low cortisol 
levels in patients with liver disease are 
nondiagnostic, particularly in hypoalbu-
minemic patients. and of little clinical 
significance ill, 27). We disagree with 
Crit Care Med 2005 Vol. 33, No. 6 
this contention. Few would argue that a 
serum cortisol level of 8 f,Lg/dL in a crit-
ically ill leU patient is normal. We found 
no correlation between the serum corti-
sol and serum-albumin levels, negating 
the postulate that low cortisol levels may 
merely be a function of low levels of cor-
tisol binding globulin with normal free 
cortisol levels (11). Furthermore, the he-
modynamic response to hydrocortisone 
(Table 2) provides compelling evidence to 
support the contention that low cortisol 
levels are clinically relevant and that 
treatment with hydrocortisone may be 
beneficial. 
The association between low serum 
HDL levels and adrenal insufficiency that 
we observed in this study further sup-
ports the notion that liver disease may 
lead to impaired cortisol synthesis. The 
adrenal gland does not store cortisol; in-
creased secretion arises due to increased 
synthesis under the control of adrenocor-
ticotropin. Cholesterol is the principal 
precursor for steroid biosynthesis in ste-
roidogenic tissue. At rest and during 
stress, about 80% of circulating cortisol 
is derived from plasma cholesterol, the 
remaining 20% being synthesized in situ 
from acetate and other precursors (28). 
Experimental studies suggest that HDL is 
the preferred lipoprotein source of steroi-
dogenic substrate in the adrenal gland 
(29). Recently, mouse SR-B1 (scavenger 
receptor, class B, type 1) and its human 
homolog (CLA-l) have been identified as 
the high-affinity HDL receptors mediat-
ing selective cholesterol uptake (30-32). 
These receptors are expressed at high lev-
els in the parenchymal cells of the liver 
and the steroidogenic cells of the adrenal 
glands, ovary, and testis (33). CLA-1 mes-
senger RNA is highly expressed in human 
adrenals, and the accumulation of CLA-1 
messenger RNA is regulated by adreno-
corticotropin in primary cultures of nor-
mal human adrenocortical cells (34). 
'I 
Apolipoprotein (apo)A-l, the major 
protein component of HDL, is synthe-
sized principally by the liver and to a 
lesser degree in the intestine. Cicognani 
and coauthors (35) demonstrated a strik-
ing decrease in the level of serum HDL in 
patients with cirrhosis that was related to 
the severity of disease (Childs class). We 
therefore suggest that the low levels of 
HDL in patients with liver disease may be 
pathogenetically linked to the high inci-
dence of adrenal failure in this group of 
patients. Indeed, van der Voort and col-
leagues (24) demonstrated that in criti-
cally ill patients, low HDL levels were 
associated with an attenuated response to 
cosyntropin. ApoA-l has been reported to 
have a plasma half-life of 5.8 days (36). 
The half-life of apoA-1 may explain the 
lower incidence of adrenal failure in pa-
tients with acute as apposed to chronic 
liver failure and may also explain the de-
layed recovery of adrenal function after 
tolerogenic transplant. The very high in-
cidence of adrenal insufficiency immedi-
ately after liver transplantation may also 
be ascribed to the fact that the apoA-I 
factory (liver) is removed for a number of 
hours during surgery (anhepatic phase) 
as well as the fact that the transplanted 
liver suffers both an ischemic and reper-
fusion injury. However, the large dose of 
methylprednisolone given intraopera-
tively may have contributed to the blunt-
ing of the hypothalamic-pituitary-adrenal 
axis. Before the use of steroid-sparing im-
munosuppression, the standard immuno-
suppressive regimen included glucocorti-
coids, which serendipitously treated the 
concomitant adrenal insufficiency until 
both hepatic and adrenal function nor-
malized. 
Apart from low HDL levels and the 
reduced delivery of substrate for cortisol 
synthesis, other mechanisms may con-
tribute to the pathophysiology of the 
hepatoadrenal syndrome. Patients with 
acute and chronic liver disease have in-
creased levels of circulating endotoxin (li-
popolysaccharide) and prointlammatory 
mediators such as tumor necrosis factor 
(TNF)-a (21, 22). It is postulated that 
intestinal bacterial overgrowth with in-
creased bacterial translocation together 
with reduced Kupffer cell activity and 
porto-systemic shunting results in sys-
temic endotoxemia with increased tran-
scription of pro inflammatory mediators 
(21, 22). In addition, our group has pre-
viously demonstrated that serum endo-
toxin levels increase further during the 
anhepatic phase of liver transplantation 
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Patients with liver failure and pa-
tients post-liver 
transplantation have an ex-
ceedingly high incidence of 
adrenal failure, which may 
be pathophysiologically re-
lated to low levels of high-
density lipoprotein. 
and remain high for several days follow-
ing transplantation (37-39). Lipopolysac-
charide as well as TNF-lX may inhibit cor-
tisol synthesis. Endotoxin has been 
shown to bind with high affinity to the 
HDL receptor (Cia-I) with subsequent in-
ternalization of the receptor (40, 41). Li-
popolysaccharide may therefore limit the 
delivery of HDL cholesterol to the adrenal 
gland. Furthermore, TNF-ex. as well as in-
terleukin-1f3 and interleukin-6 has been 
demonstrated to decrease hepatocyte syn-
thesis and secretion of apoA-1 (42). In 
critically ill surgical patients, Gordon and 
colleagues (43) demonstrated an inverse 
relationship between interleukin-6 levels 
and apoA-I. In addition to its effects on 
apoA-1, TNF-ex. has been demonstrated to 
directly inhibit cortisol synthesis in a 
dose-dependent manner (44). TNF-ex. may 
also cause tissue resistance to cortisol by 
decreasing the number of glucocorticoid 
receptors or by up-regulating FK binding 
protein 51, which prevents the cortisol! 
cortisol receptor/heat shock protein-90 
complex from moving into the nucleus 
(15, 16, 45-49). 
Our study is limited by the fact that it 
is an observational, noninterventional 
study. Additional limitations include the 
fact that the free serum cortisol, cortisol 
binding globulin, and aldosterone levels 
were not measured. Nevertheless, using 
"conservative" diagnostic criteria, we re-
port a surprisingly high incidence of ad-
renal insufficiency in a large cohort of 
critically ill patients with liver disease. 
We believe that treatment with hydrocor-
tisone is indicated in hemodynamically 
unstable patients with the hepatoadrenal 
syndrome. In addition, hydrocortisone 
may be beneficial in patients with the 
hepatoadrenal syndrome with unex-
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plained altered mental status or unex-
plained fever. 
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